SILVA, I. A.L ., Tereza DOUSOVA, S. RAMALHO, R. CENTEIO, L. A. CLARKE, V. RAILEAN, H. M. BOTELHO, Andrea HOLUBOVA, Iveta VALÁŠKOVÁ, J. T. YEH, T. C. HWANG, C. M. FARINHA, K. KUNZELMANN and M. D. AMARAL. Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A > G. Biochimica et Biophysica Acta - Molecular Basis of Disease. Amsterdam: ELSEVIER SCIENCE BV, 2020, vol. 1866, No 11, p. 1-10. ISSN 0925-4439. Available from: https://dx.doi.org/10.1016/j.bbadis.2020.165905.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A > G
Authors SILVA, I. A.L . (620 Portugal), Tereza DOUSOVA (203 Czech Republic), S. RAMALHO (620 Portugal), R. CENTEIO (620 Portugal), L. A. CLARKE (620 Portugal), V. RAILEAN (620 Portugal), H. M. BOTELHO (620 Portugal), Andrea HOLUBOVA (203 Czech Republic), Iveta VALÁŠKOVÁ (203 Czech Republic, belonging to the institution), J. T. YEH (840 United States of America), T. C. HWANG (840 United States of America), C. M. FARINHA (620 Portugal), K. KUNZELMANN (276 Germany) and M. D. AMARAL (620 Portugal, guarantor).
Edition Biochimica et Biophysica Acta - Molecular Basis of Disease, Amsterdam, ELSEVIER SCIENCE BV, 2020, 0925-4439.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.187
RIV identification code RIV/00216224:14110/20:00116370
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.bbadis.2020.165905
UT WoS 000561985900013
Keywords in English CFTR modulators; Theranostics; Rare mutations; Intestinal organoids; Precision medicine
Tags 14110323, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 9/9/2020 08:08.
Abstract
Background: For most of the > 2000 CFTR gene variants reported, neither the associated disease liability nor the underlying basic defect are known, and yet these are essential for disease prognosis and CFTR-based therapeutics. Here we aimed to characterize two ultra-rare mutations - 1717-2A > G (c.1585-2A > G) and S955P (p.Ser955Pro) - as case studies for personalized medicine. Methods: Patient-derived rectal biopsies and intestinal organoids from two individuals with each of these mutations and F508del (p.Phe508del) in the other allele were used to assess CFTR function, response to modulators and RNA splicing pattern. In parallel, we used cellular models to further characterize S955P independently of F508del and to assess its response to CFTR modulators. Results: Results in both rectal biopsies and intestinal organoids from both patients evidence residual CFTR function. Further characterization shows that 1717-2A > G leads to alternative splicing generating < 1% normal CFTR mRNA and that S955P affects CFTR gating. Finally, studies in organoids predict that both patients are responders to VX-770 alone and even more to VX-770 combined with VX-809 or VX-661, although to different levels. Conclusion: This study demonstrates the high potential of personalized medicine through theranostics to extend the label of approved drugs to patients with rare mutations.
PrintDisplayed: 23/7/2024 22:11